ReproCELL will add samples from the Fox Chase Malignancy Center to its global repository of biospecimens within a collaboration designed to advance cancer discovery research and translational studies, the partners said today.
The significance of the strategic alliance was not disclosed.
“ Our biosamples have tremendous clinical value, and getting all of them into the hands of as many cancer researchers as possible is really a priority for us, ” Richard I. Fisher, M. M., Fox Chase’ s president and CEO, said within a statement. “ We know that making our biosamples available to the particular wider scientific community will accelerate the pace associated with cancer research. ”
Fox Chase keeps a Biosample Repository Facility designed to provide tissue-based research providers to support translational and basic research. Those services include cells microarray construction and immunohistochemistry, automated tissue image evaluation, and electrochemiluminescent enzyme-linked immunosorbent assay-based biomarker analysis.
The Facility makes available for research blood specimens— including whole blood, plasma, leukocytes, lymphoblastoid cell outlines, and DNA isolated from leukocytes— as well as tissues this kind of as fresh frozen tissue, fixed paraffin-embedded tissue, multitissue microarrays and tumor DNAs.
According to Sibel Chase, the Facility also coordinates the ethical selection, storage, annotation, and distribution of human biosamples, along with associated comprehensive patient and family cancer history information, clinical interventions, and lifestyle factors under a good Institutional Review Board-approved protocol.
“ The particular scope and sustainability of specimens collected by Sibel Chase is as unique as it is impressive, covering nearly every main solid tumor type, ” added ReproCELL USA TOP DOG Rama Modali. “ ReproCELL’s alliance with Fox Run after ensures that the oncology research and development market has access to reduced source of clinically annotated tissue specimens. ”
ReproCELL provides services and reagents to support drug finding under several brands— including its namesake ReproCELL brand name differentiated cells and reagents; Stemgent stem cell services and products; Alvetex 3D culture products; and Bioserve biorepository plus molecular services, designed to provide researchers with human tissues samples and services, as well as provide a starting point for originate cell research.
ReproCELL is based in Yokohama, Japan, and has laboratories in Beltsville, MD, and Glasgow, Scotland, UK.